Auxilium On a Roll ...
Health Care: Drugs
Neuralstem Inc. (CUR: AMEX)
$0.92 -0.01 | -1.06%
06/04/12 - 03:56 PM ET
Ratio Comparisons
| Company | Industry | S&P 500 | |
| Valuation Ratios | |||
|---|---|---|---|
| P/E Ratio (TTM) | n.a. | 75.30 | 17.70 |
| P/E High - Last 5 Yrs | n.a. | n.a. | 67.70 |
| P/E Low - Last 5 Yrs | n.a. | n.a. | 12.50 |
| Beta | 1.02 | 0.58 | 0.98 |
| Price to Sales (TTM) | 91.99 | 4.62 | 1.42 |
| Price to Book (MRQ) | 11.10 | 3.44 | 2.41 |
| Price to Tangible Book (MRQ) | 13.19 | 6.74 | 5.08 |
| Price to Cash Flow (TTM) | -4.30 | 26.10 | 9.80 |
| Price to Free Cash Flow (TTM) | -6.00 | 48.80 | 17.40 |
| Dividends | |||
| Dividend Yield (%) | 0.00 | 0.50 | 2.10 |
| Dividend Yield - 5 Yr Avg (%) | n.a. | 0.20 | 2.20 |
| Dividend 5 Yr Growth Rate (%) | n.a. | n.a. | -0.76 |
| Payout Ratio (TTM) | 0.00 | 3.00 | 30.00 |
| Sales (MRQ) vs Qtr 1 Yr Ago (%) | n.a. | 9.90 | 11.80 |
| Sales (TTM) vs TTM 1 Yr Ago (%) | -46.70 | 7.70 | 9.20 |
| Growth Rates (%) | |||
| Sales - 5 Yr Growth Rate (%) | n.a. | 9.03 | 1.79 |
| EPS (MRQ) vs Qtr 1 Yr Ago (%) | n.a. | 18.50 | 17.50 |
| EPS (TTM) vs TTM 1 Yr Ago (%) | n.a. | 18.50 | 17.50 |
| EPS - 5 Yr Growth Rate (%) | n.a. | n.a. | -1.66 |
| Capital Spending - 5 Yr Growth Rate (%) | 39.56 | -4.13 | -1.17 |
| Financial Strength | |||
| Quick Ratio (MRQ) | 2.30 | 2.90 | 1.10 |
| Current Ratio (MRQ) | 2.50 | 3.50 | 1.60 |
| LT Debt to Equity (MRQ) | 0.00 | 0.41 | 0.82 |
| Total Debt to Equity (MRQ) | 0.00 | 0.45 | 0.96 |
| Interest Coverage (TTM) | n.a. | 6.20 | 5.50 |
| Profitability Ratios (%) | |||
| Gross Margin (TTM) | n.a. | 84.10 | 46.90 |
| Gross Margin - 5 Yr Avg | n.a. | 83.50 | 47.70 |
| EBITD Margin (TTM) | n.a. | 27.30 | 18.90 |
| EBITD - 5 Yr Avg | -2,891.36 | 0.00 | 0.00 |
| Pre-Tax Margin (TTM) | n.a. | 14.10 | 12.10 |
| Pre-Tax Margin - 5 Yr Avg | n.a. | 10.60 | 10.30 |
| Management Effectiveness (%) | |||
| Net Profit Margin (TTM) | -21.70 | 0.10 | 0.09 |
| Net Profit Margin - 5 Yr Avg | n.a. | 5.30 | 7.00 |
| Return on Assets (TTM) | -173.40 | 4.70 | 3.10 |
| Return on Assets - 5 Yr Avg | -191.00 | 2.20 | 2.50 |
| Return on Investment (TTM) | -261.00 | 6.10 | 7.90 |
| Return on Investment - 5 Yr Avg | -382.00 | 2.80 | 6.50 |
| Efficiency | |||
| Revenue/Employee (TTM) | 39,063.00 | 701,747.00 | 449,376.00 |
| Net Income/Employee (TTM) | -847,822.00 | 83,589.00 | 39,003.00 |
| Receivable Turnover (TTM) | 4.70 | 5.80 | 7.60 |
| Inventory Turnover (TTM) | n.a. | 1.30 | 8.30 |
| Asset Turnover (TTM) | 0.10 | 0.40 | 0.40 |
Portfolios with CUR
- Portfolio NameUser Type
- Userdennis diamonds
- UserMy Folly
- ContributorStem Cell Stocks
- UserRAPTOR SPRTD-0902092107
- UserBlogue's Picks
- Userbrownmark68 Portfolio 1
- UserBENIRANS II
- UserEnergy and Options
Latest CUR Headlines from TheStreet
- 9 Biotech Penny Stocks to Buy 08.31.10 | 10:08 am
- Interstate Hotel, Neuralstem: Midday Volume Plays 12.18.09 | 01:12 pm
- Four Must-See Charts: Stem Cell Stocks 07.02.09 | 03:07 pm
- Stem cell firms jump on Obama policy plans 03.06.09 | 06:03 pm
- Wednesday's Health Winners & Losers 09.19.07 | 04:09 pm
Press Releases for CUR
- DiagnoCure To Host Q2 2012 Conference Call And Webcast - PR Newswire 05.30.12 | 07:05 am
- PCA3 Test Featured At American Urological Association Meeting - PR Newswire 05.25.12 | 07:05 am
- Neuralstem CEO To Present At The World Stem Cells And Regenerative Medicine Congress In London - PR Newswire 05.21.12 | 09:05 am
- DiagnoCure Issues Statement On Acquisition Of Gen-Probe By Hologic - PR Newswire 05.01.12 | 12:05 pm
- Neuralstem ALS Stem Cell Trial Interim Results Reported In The Journal, STEM CELLS - PR Newswire 03.28.12 | 09:03 am
- Fourteenth Patient Dosed In Neuralstem ALS Stem Cell Trial - PR Newswire 03.07.12 | 09:03 am
- PROGENSA® PCA3 Featured At European Association Of Urology Congress In Paris - PR Newswire 02.29.12 | 04:02 pm
- FDA Approves Gen-Probe's PROGENSA® PCA3 Assay, First Urine-Based Molecular Test To Help Determine Need For Repeat Prostate Biopsies - PR Newswire 02.15.12 | 07:02 am
- Neuralstem Announces Closing Of $5.2-Million Registered Direct Offering - PR Newswire 02.14.12 | 11:02 am
- Neuralstem President And CEO To Present At BIO CEO & Investor Conference 2012 - PR Newswire 02.08.12 | 09:02 am
Partner Headlines for CUR
- End-of-Day Market Summary for November 23, 2011 - Benzinga 11.23.11 | 04:11 pm
- Neuralstem Loses $0.08/Share in Q2 - Seeking Alpha 08.11.11 | 09:08 am
- Zacks' Voice of the People highlights opportunities with Citigroup, Neuralstem, Primerica, PDL Biopharma - Press Releases - Zacks 04.28.10 | 09:04 am
- Data Mining - With Your OWN Spreadsheets - Voice of the People - Zacks 04.27.10 | 06:04 pm
